RSS   Newsletter   Contact   Advertise with us
Post Online Media

Novelion Therapeutics appoints Mark Corrigan to board

Novelion TherapeuticsNovelion Therapeutics, a developer of new standards of care for individuals living with rare diseases, announced the appointment of Mark Corrigan to its board of directors.

Dr. Corrigan will serve as a member of the compliance committee.

Dr. Corrigan was previously president and chief executive officer of Zalicus Inc.

Prior to that, Dr. Corrigan was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals).

Prior to joining Sepracor, he spent 10 years with Pharmacia & Upjohn, most recently as group vice president of global clinical research and experimental medicine.

Dr. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. and on the supervisory board of Nabriva Therapeutics AG.

He previously served as a director of CoLucid Pharmaceuticals, Avanir Pharmaceuticals, EPIRUS Biopharmaceuticals, and Cubist Pharmaceuticals.

Dr. Corrigan was chairman of the board of EPIRUS and served on the audit committee and nominating and governance committee and chaired the scientific affairs committee of Cubist’s board.

Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology.

He holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

 LATEST MOVES FROM British Columbia 

More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy